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Although immune cells can be divided into numerous subsets, they can be broadly categorized as either myeloid or lymphoid, and involved in either innate or adaptive immunity. Although not all innate immune cells are myeloid, all adaptive immune cells are lymphocytes (classical B cells and T cells). A cell of the adaptive immune system is one that is able to successfully rearrange its antigen-binding molecule (that is, B cell receptor or antibody, or T cell receptor (TCR)) and proliferate to create a diverse population of cells capable of recognizing a wide range of potential pathogen epitopes. Naive B cells and naive T cells need to be primed by antigen-presenting cells (APCs) displaying antigen in order to mature into fully competent antibody-secreting B cells or effector T cells. By contrast, receptors controlling the activation of innate immune cells do not undergo somatic rearrangement and therefore do not show such diversity. Rather, these receptors evolved to rapidly respond to common pathogen-associated molecular patterns, typically with mass cytokine production and cytolysis of infected cells, which limits the spread of infection before the adaptive immune system is mobilized to clear the infection (FIG. 1) .
The immune system is conceptualized as recognizing pathogenic microbial attack to maintain life in the literal (and later metaphorical) 'sea' of potential infectious agents in which multicellular life evolved. However, the real situation is much more complex, with microorganisms masquerading as 'self ' , and commensal organisms (some of which even benefit the host) becoming opportunistic pathogens a day, year or decade later. Furthermore, the 'self ' can become aberrantly recognized as the 'other' (that is, foreign) and stimulate immune responses that would normally be protective. While in many individuals this will not lead to clinical symptoms, in those predisposed and exposed to particular microorganisms, this does eventually lead to one or more of the spectra of autoimmune diseases.
Acute inflammation is a critical mechanism for protecting the host against infection and tissue injury. Such inflammation, whether infectious or sterile in origin, is characterized by immune cell infiltration into target tissues to orchestrate the killing and removal of either infected or damaged cells (FIG. 1 [1] [2] [3] , George C. Tsokos 4 , Kingston H.G. Mills 5 , Dirk Elewaut 6, 7 and Ben Mulhearn 1, 8, 9 Abstract | Many rheumatic diseases are characterized by having an autoimmune background. Determining the mechanisms underlying autoimmunity is, therefore, important to further understand these diseases and to inform future lines of research aimed at developing new treatments and cures. As fast responders, innate lymphocytes have protective or pathogenic roles in the initiation as well as the maintenance of immune responses in general, and they contribute to tissue homeostasis, among other functions. Innate lymphocytes also seem to be involved in autoimmunity in particular. Since 2010, accumulating evidence clearly shows that different populations of innate lymphocytes have roles in responding to antigen-specific autoantibody and autoreactive T cells, thereby amplifying or attenuating disease processes. Cytotoxicity is a cardinal feature of many innate lymphocytes and can contribute to inflammatory tissue damage. Finally, innate lymphocytes can respond to biologic therapies for autoimmune diseases. Consequently, like TNF and other effector molecules, certain innate lymphocyte subsets might be appropriate therapeutic targets to ameliorate various autoimmune diseases. In this Review, we summarize the main characteristics and functions of innate lymphocyte subsets, and describe their roles in autoimmune disease. We also discuss how biologic therapies influence innate lymphocyte function and consider the potential for these cell subsets to act as future therapeutic targets.
Regulatory T cells
(T reg cells). Cells characterized by the production of IL-10 as well as high expression of CD25 (IL-2 receptor subunit-α) and the co-stimulation blocker cytotoxic T-lymphocyte antigen 4 (CTLA4). T reg cells keep the immune system in check by inhibiting other cells of the immune system. resolve owing to the continued presence of an inducer of inflammation or a lack of normal immunoregulation. The excessive and persistent presence of cytotoxic immune cells and their mediators has important roles in the pathogenesis of numerous human diseases, including autoimmune diseases. Restoring the balance of the healthy immune system is one approach to treat autoimmune disease. The restoration of health in autoimmune diseases has already been subject to a quantum leap forward with the advent of biologic therapies, and newer approaches are expected to contribute further. When developing effective anti-inflammatory interventions, therefore, the challenge remains to identify those components and pathways that are primarily pathogenic and to develop strategies that mitigate their pathogenic effects without substantially compromising the protective functions of the immune system as a whole or inducing further complications, such as an increased susceptibility to infection or cancer. Understanding the targets in autoimmune diseases promises improved therapeutic control.
This Review focuses on subsets of innate lymphocytes (TABLE 1) -which have been described using various terms, including innate lymphoid cells (ILCs), innatelike lymphocytes and unconventional T cells 1,2 -and we clarify the relevant nomenclature. At first, the terms 'innate' and 'lymphocyte' might seem to be mutually exclusive; however, we use the term 'innate lymphocyte' to refer to cells that are found in a mature state 'ready for action' . These cells can be classified into two broad groups. The first group comprises cells that are derived from the lymphoid lineage but do not undergo any receptor re arrangement: natural killer (NK) cells, other subsets of ILCs, and innate-like B (ILB) cells. The second group comprises so-called unconventional T cells that have similar characteristics to conventional T cells and rearrange their TCRs, but are selected on monomorphic MHC-related restriction molecules during their development in the thymus, which results in a restricted T cell repertoire 2 . This group includes T cells that do not use the α-chain or β-chain of the TCR (namely γδ T cells) and those that mostly recognize non-peptide antigens in the absence of classical MHC molecules (mucosal associated invariant T (MAIT) cells and NKT cells). These cell subsets are also considered as innate because they rapidly produce large amounts of cytokines following the recognition of certain fixed molecular patterns, much like other innate immune cells.
Innate lymphocytes share a common ability to enter tissues (rather than being found in lymphoid organs, like the majority of classical B cells and T cells). Accordingly, only innate lymphocytes and a subset of effector memory T cells and regulatory T cells (T reg cells) are appropriately positioned to positively or negatively influence tissuespecific autoimmune diseases 3 . As described below, generic versus disease-specific and stage-specific differences in immune cell phenotype and function have been described in various autoimmune diseases. Many subsets of innate lymphocytes, as well as other cytotoxic immune cells, evolved to kill infected cells and amplify immune responses by producing proinflammatory cytokines, so the observation that collateral damage can contribute to inflammation and ultimately autoimmune disease is not surprising. Other innate lymphocyte subsets can modulate inflammation, so the balance between the number of proinflammatory and regulatory cells within a local environment is probably critical in determining the type of immune response. Ultimately, although some subsets of innate lymphocytes show generic changes in autoimmune and even other inflammatory diseases, they might not show specificity for a disease, stage or treatment in comparison to other subsets, as we discuss in this article. An improved understanding of the generic and specific roles of innate lymphocytes in autoimmunity will inform the development of new therapies.
In this Review, we discuss the characteristics and functions of each innate lymphocyte subset (see TABLE 1 for an overview) and summarize our current understanding of their roles in the context of autoimmunity, focusing mainly on rheumatic diseases but also drawing from findings in other autoimmune conditions. We also describe the impact of biologic therapies on innate lymphocyte populations and the prospects for targeting innate lymphocytes therapeutically. 4 . The association of autoimmunity with prior infection could partly involve downregulation of MHC class I molecules, which could unleash NK cell activity 5 . The role of NK cells in autoimmunity is as yet unclear. Impairment of NK cell cytotoxicity has been implicated in autoimmune diseases such as systemic lupus erythematosus (SLE) 6 , and NK cells have also been shown to provide an important early source of IFNγ, which enhances the expression of integrin β1 (also known as very late antigen 4 (VLA4)) on T cells and consequently promotes the migration of autoreactive T cells into the central nervous system (CNS) 7 . NK cell cytotoxicity and proinflammatory activities might at first seem deleterious, but mouse NK cells can secrete restorative neurotropic factors such as brain-derived neurotrophic factor (BDNF) and neurotrophin 3 (NT3) 8 , which are protective in the context of CNS autoimmunity. However, it is important to note that findings from mice do not always reflect the human setting . Consistent with these data suggesting an increase in the activity of T H 1-cytokine-producing NK cells in auto immune diseases, increased numbers of activated IFNγ-producing CD56
ILCs

NK cells
hi NK cells are found in synovial fluid from patients with Lyme arthritis (regardless of whether their arthritis responded to antibiotic therapy), further suggesting that these cells contribute to excessive inflammation and immune dysregulation in joints 12 .
As well as increased NK cell cytokine production, NK cell cytotoxicity seems to be increased in some autoimmune rheumatic diseases. Granulysin-positive T cells, and CD56 low and CD56 hi NK cells are more frequent and more brightly stained in peripheral blood leukocyte samples from patients with psoriatic arthritis (PsA) than in samples from healthy controls 13 . Also, NK cells from patients with active PsA show higher levels [103] [104] [105] ) encodes C-type lectin superfamily members (including CD94, CD161 and the NKG2 subfamily) that are expressed on many innate lymphocytes. NK cell receptors (NKRs), including NK locus molecules, are common to NK cells, NKT cells and other innate lymphocyte subsets. Note that the NK locus and NKRs in general are not expressed by naive B cells or T cells, but are expressed by some effector or memory mature T cells, particularly cytotoxic CD8 + and tissue-tropic helper CD4 + memory adaptive T cell subsets. Consequently, ~25% of adult human T cells express CD161, for example 104 . ‡ Bacterial control refers to commensal mucosal bacteria as well as invasive pathogens. BCR, B cell receptor; CRTH2, chemoattractant receptor-homologous molecule expressed on T helper type 2 (T H 2) cells (also known as prostaglandin D2 receptor 2); EAE, experimental autoimmune encephalomyelitis; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL-7Rα, IL-7 receptor-α; ILC, innate lymphoid cell; iNKT, invariant NKT; KIR, killer cell immunoglobulin-like receptor; KLRG1, killer cell lectin-like receptor subfamily G member 1; MR1, MHC class I-related molecule; MS, multiple sclerosis; PsA, psoriatic arthitis; RA, rheumatoid arthritis; ST2, interleukin-1 receptor-like 1; TCR, T cell receptor; TLR, Toll-like receptor.
T H 17
(T helper type 17). A term that is used to refer to an immune response characterized by the production of cytokines of the IL-17 family. IL-17 is a proinflammatory cytokine produced by T H 17 cells, as well as group 3 innate lymphoid cells and γδ T cells.
of granulysin-mediated cytotoxicity than do those from patients in remission or those from healthy controls 13 . These results suggest that granulysin-mediated NK cell cytotoxicity could contribute to PsA. However, NK cells from patients with SLE can show reduced cytotoxicity and be less responsive to IFNβ 14, 15 , suggesting that cytotoxic NK cells might have disease-specific roles in different autoimmune conditions.
Other ILC subsets
The term ILC (reviewed elsewhere 16 ) was first coined in 2010 (REF. 1) and represents a family of leukocytes that seem to have important roles in bridging innate and adaptive immunity. Importantly, and similarly to NK cells, other ILC subsets do not express rearranged antigen receptors in the same way as conventional B cells and T cells do. Furthermore, some ILC subsets express NK cell markers (TABLE 1) , making discrimination and targeting of each subset complicated.
When organs are injured during the onset of autoimmune diseases, APCs elicit immune responses by producing factors such as TNF, transforming growth factor-β (TGFβ) and reactive oxygen species (ROS), which can stimulate ILCs as well as other lymphocytes. ILCs are classified into subsets according to the cytokine profile of the T helper cell subset they mirror: group 1 ILCs, comprising conventional (circulating) NK , and ILC3s produce IL-17-related cytokines, which have roles in the axial spondyloarthropathies and psoriasis 18 . ILC2s, although not yet implicated in autoimmunity, might promote other immunemediated diseases such as asthma and allergy 19, 20 . ILC3s, however, are also important sources of the homeostatic cytokine IL-22, which is involved in epithelial maintenance; for example, in a mouse model of colitis, IL-22 from ILC3s protects against the development of autoimmune colitis 21 . Conclusive roles for the various ILC subsets in autoimmune disease might be more forthcoming as their characterization and our understanding improves in the near future.
NKT cells NKT cells carry the hallmarks of both NK cells and T cells, and they are functionally defined as being CD1d-restricted, as their TCR recognizes antigen presented by CD1d molecules on APCs 22 . NKT cells are postulated to have diverse biological functions 23 . These cells have CD1d-specific cytotoxicity, and are also able to rapidly produce high levels of various cytokines and chemokines, including both T H 1 and T H 2 cytokines, following stimulation with different endogenous and exogenous ligands 24 . In humans and mice, NKT cells have physiological roles in antitumour and antiviral responses 25, 26 . The term 'NKT cells' encompasses a variety of cells with different phenotypes 27 . The best-described are invariant NKT (iNKT) cells, which have also been referred to as type 1 or classical NKT cells, but there are also non-invariant ('diverse' or 'type 2') CD1d-reactive NKT cell populations in blood and tissues.
In humans, iNKT cells express the invariant TCR with the Vα24-Jα18 α-chain rearrangement paired with the Vβ11 chain 28 , forming a TCR that is restricted to recognizing lipid antigens such as α-galactosylceramide (α-GalCer) and related α-conformation glycolipids, which can be derived from various bacteria (including commensal gut Bacterioides as well as Lyme disease Borrelia species) and other organisms. Endogenous ligands required for iNKT cell selection, which are still being characterized, could be more directly involved in sterile inflammation that leads to autoimmunity. In common with other innate lymphocytes, iNKT cells can also be stimulated by inflammatory cytokine combinations in the absence of lipid ligands or infections 29 .
Owing to their ability to rapidly produce both T H 1 and T H 2 cytokines following antigenic stimulation, researchers have become interested in the role of NKT cells in supporting the type 1 and type 2 cytokine responses of classical CD4 + T cells, and thus the study of NKT cells has become a key area of research in autoimmunity 30 .
Box 1 | Mouse versus man
Overall similarities are found between human and model-animal innate lymphocyte subsets, as with other immune cells. Although much has been learnt from mice and other animal models, the mouse and human immune systems have evolved to handle only a partially overlapping spectrum of infectious organisms. Although both mice and humans are of course mammals, mouse physiology is clearly very different from human physiology, and certain organ systems are particularly different, such as the skin -the distinction is not just related to the presence of fur versus limited hair but to major differences in immune components. For instance, healthy mouse skin contains large proportions of γδ T cells, originally called dendritic epidermal cells (DECs), whereas human skin contains proportionally fewer γδ T cells, but contains more αβ T cells than peripheral blood 100 . Nonetheless, overall similarities are underscored by often similar, although far from identical, aetiologies of autoimmunity in man (for example, rheumatoid arthritis versus other non-autoimmune arthropathies, systemic lupus erythematosus, type 1 diabetes mellitus and different inflammatory bowel diseases) and mouse (collagen-induced arthritis, lupus-like and non-obese diabetic (NOD) mouse strains, and dextran sulfate sodium (DSS)-induced and oxazalone-induced colitis models). For example, IL-17 production by mouse and human skin γδ T cells are features of psoriasis models and clinical disease, but in humans it is the circulating Vγ2Vδ2 T cells that relocate and produce much of the IL-17 rather than the resident γδ1 + subset 61, 64, 65 . Furthermore, human autoimmune diseases reflect years of chronic inflammation in a much larger, longer-lived organism that can have variable lifestyles. Comorbidities, previous pathogen exposures (compared with standard animal facility specificpatho gen-free (SPF) mice and other model animals with various relatively homogeneous microbiomes) and genetic heterogeneity all contribute to limitations between model and clinical diseases. Lack of knowledge of the aetiology of most human autoimmune diseases limits our ability to accurately model disease and thus current models are at best suboptimal. Nonetheless, much had been learned from in vivo model studies and some has translated into effective treatments for autoimmune diseases. A model of autoimmune disease is, like art (as pointed out by Pablo Picasso), "a lie that tells the truth"! T H 0 (T helper of no type). A terms that used to refer to naive T cells that have not yet encountered their cognate antigen and are able to become an effector or a memory T cell.
A protective role in autoimmunity?
NKT cells seem to have a protective role in some autoimmune diseases. The number of circulating iNKT cells is reduced in patients with RA, SLE, systemic sclerosis and Sjögren syndrome compared with that in healthy controls 31, 32 . Interestingly, iNKT cell frequency is inversely correlated with the 28-joint Disease Activity Score (DAS28) in patients with RA 33 and, compared with iNKT cells from healthy individuals, iNKT cells from patients with early RA show reduced proliferation in vitro, which is apparently independent of CD1d function 33 . Similarly, the frequency and in vitro proliferation of iNKT cells are significantly reduced in patients with adult-onset Still disease compared with healthy controls, and iNKT cells from these patients show increased levels of apoptosis 34 . An important point to note here is that the reduction in circulating numbers of NKT cells is unlikely to be a consequence of glucocorticoid treatment in patients with autoimmune diseases; glucocorticoids do reduce the frequency of most types of circulating T cell, but iNKT cells are relatively resistant to this effect and might actually show increased proliferation in response to glucocorticoids 35 . Of course, circulating cell numbers do not well reflect tissue localization. In any event, clinical information including concurrent treatments is desirable in these studies, as concurrent treatment with multiple disease-modifying drugs including glucocorticoids is a common and well-known confounding factor in studies of patients with autoimmune diseases.
Similarly to patients with RA and adult-onset Still disease, patients with SLE show defective iNKT cell homeostasis, a phenotype relating to the role of B cells in the development of both mouse and human iNKT cells 36 . B cells from patients with SLE show reduced CD1d expression compared with those from controls 36 . Notably, iNKT cell number and function are restored in patients with SLE who respond to anti-CD20 treatment, with normalization of CD1d expression on repopulating immature B cells 36 . However, the expansion of innate-like CD5 + IL-10-producing B cells (now known as regulatory B cells (B reg cells) or 'B10' cells, discussed below), rather than iNKT cells themselves, protects against experimental lupus by reducing the production of IL-17A and IFNγ by CD4 + T cells 37 . In addition to reduced frequency and proliferation, iNKT cell function might also be defective in autoimmune diseases. For example, compared with iNKT cells from healthy controls, those from patients with adultonset Still disease lose the ability to proliferate in response to stimulation with α-GalCer 34 . In addition, NK cell cytotoxicity, stimulated indirectly through α-GalCeractivated iNKT cells, was markedly reduced in patients with Still disease compared with healthy controls 34 . Interestingly, iNKT cell deficiency correlated with both reduced NK cell activity and increased disease severity.
Providing further evidence of a protective role of iNKT cells in autoimmune diseases, symptoms of gut and joint inflammation in a mouse model of spondyloarthritis (SpA) induced by TNF overexpression were aggravated in mice lacking CD1d compared with CD1d-sufficient mice 38 . In CD1d-sufficient mice, iNKT cell activation during disease was associated with the enrichment of CD1d hi inflammatory dendritic cells (DCs), particularly at draining lymph nodes. These inflammatory DCs induced iNKT cells to produce immunomodulatory cytokines. A similar increase in CD1d hi DCs was observed in patients with SpA
38
. iNKT cells have also been reported to have a protective role through effects on osteoclastogenesis and inflammatory bone destruction in RA. α-GalCer-stimulated human iNKT cells inhibit osteoclastogenesis partly via IFNγ, and α-GalCer-treated mice show attenuation of arthritis, reduced levels of synovial proinflammatory cytokines and decreased bone destruction 39 . The positive effects of αGalCer on in vitro osteoclastogenesis and cytokine production are diminished in patients with RA, which has been suggested to reflect impaired iNKT cell function 39 . iNKT cells might also have a protective role in autoimmune disease through effects on B cells; for example, in an anti-DNA transgenic mouse model of lupus, iNKT cells inhibit autoreactive B cells in a cell-contact-mediated manner via CD1d 40 . Finally, a considerable amount of data from mouse models is consistent with the involvement of iNKT cells in protection against Lyme disease; iNKT cell stimulation by Borrelia glycolipids induces these cells to mount a protective immune response [41] [42] [43] . In summary, although iNKT cells might have a protective role in autoimmunity, the evidence is derived either from studies in mice or from observational human studies. More research into the direct roles of these cells and the underlying mechanisms in humans 39 is clearly needed, now that potential mechanisms have been revealed in mice 36, 38, 40, 41 .
A pathogenic role in autoimmunity?
In contrast to the evidence suggesting a protective role, other studies indicate the iNKT cells can have pathogenic roles in autoimmune disease. iNKT cells from patients with Still disease produce high levels of proinflammatory cytokines 34 . Similarly, circulating iNKT cells in patients with RA have a more T H 1-biased phenotype than do those from healthy controls 33, 44 . Molecular analysis showed that the iNKT cell TCR repertoire is biased against high-affinity lipid-reactive iNKT clones specifically in patients with early RA 33 . Compared with the broad T H 0-like profiles of all iNKT cells in healthy controls, the residual high-affinity iNKT cells had a T H 1 bias in treatment-naive patients with RA, contrasting with the T H 2-like profile of these cells in treated patients 33 . iNKT cells have also pathogenic roles through effects on B cells; a subset of iNKT cells expressing SLAM family member 6 (SLAMF6, known as LY108 in mice) can provide pathogenic help to B cells via IL-21, and can produce IL-17 in lupus-prone mice 45 . Indeed, in the same study, in vivo activation of iNKT cells by α-GalCer administration enhanced their helper activity and enhanced IgG autoantibody secretion by syngeneic B cells in two different lupus-prone mouse strains (NZB/W and B6.Sle1b) 45 . The role of iNKT cells in patients with Lyme arthritis seems to be more complex; in contrast to activated NK cells, which are uniformly present (as discussed above), iNKT cells persist in the synovial fluid of patients with antibiotic-responsive Lyme arthritis but not in those with antibiotic-refractory Lyme arthritis, suggesting that iNKT cells have disease-subtype-specific roles in this setting 12 .
In addition to iNKT cells, CD1d-restricted noninvariant NKT cells are also implicated in autoimmune disease. Non-invariant NKT cells can be reactive towards sulfatide, an endogenous lipid, and these cells accumulate in the gut of patients with ulcerative colitis 46 and the synovia of joints affected by RA 47, 48 . However, other studies provide data suggesting that non-invariant NKT cells have a protective role in autoimmune disease 49 . Based on current knowledge, NKT cells seem to have dual functions in a range of disease settings, rather than disease-specific roles. Further investigation is warranted to improve our understanding of how iNKT cells and non-invariant NKT cells contribute to autoimmune disease before these cell types can be exploited as therapeutic targets.
γδ T cells γδ T cells are much less abundant than classical αβ T cells and are distinct as they express a TCR that is rearranged from the genes encoding the TCR γ-chain and δ-chain. Far fewer gene segments encode these two chains than encode the α-chain and β-chain: only 3-5 regions encode Vδ, Dδ, Jδ, Vγ and Jγ segments, compared with (for example) 61 regions encoding the Jα segment of the αβTCR 50 . Although γδ T cells have much less diversity in their receptor segments than do αβ T cells, their TCRs can be as diverse as those of αβ T cells owing to nucleotide insertions and the insertion of multiple Dδ segments during rearrangement. In humans, the most common γδ T cell found in blood is the Vγ2Vδ2 T cell, also previously known as the Vγ9Vδ2 T cell. This population constitutes around 80% of all blood γδ T cells in humans 51 . Vγ2Vδ2 T cells do not recognize antigen in the context of MHC molecules but probably recognize free antigen in a way similar to the B cell receptor. A study published in 2012 demonstrated that phosphoantigens can be presented to the Vγ2Vδ2 TCR via an MHCrelated membrane protein known as butyrophilin subfamily 3 member A1 (also known as CD277) 52 . Vγ2Vδ2 T cells recognize phosphoantigens produced by a variety of bacteria, including mycobacteria, and they rapidly expand and produce the proinflammatory cytokines TNF and IFNγ 53, 54 . The second most common type of γδ T cell in humans is the Vδ1 T cell. These cells preferentially relocate to mucosal sites, such as the skin and gut epithelium, where they form a population of cells known as intraepithelial lymphocytes 55 . These cells might have a role in surveillance and destruction of stressed, pre-cancerous epithelial cells following engagement of the NK receptor NKG2D type II integral membrane protein by epithelial cell ligands 55 . Although Vδ1 TCR ligands are yet to be characterized, endogenously produced stress molecules such as sulfatides have been implicated 56 . Vδ1 T cells with an activated phenotype are also found enriched in peripheral sites of inflammation such as the rheumatoid synovium 57 , and they could be responding to the expression of endogenous stress ligands at these sites.
Indeed, γδ T cells have a major pathogenic role in a number of autoimmune diseases. Although memory antigen-specific γδ T cells have been described in certain infections, the γδ T cells that mediate auto immunity are innate-like, as they respond to pro inflammatory cytokines -particularly IL-23, in synergy with IL-1α, IL-1β or IL-18 -in the absence of TCR activation 58, 59 . Studies in mice with experimental autoimmune encephalomyelitis, a model of multiple sclerosis (MS), have shown that γδ T cells provide an important early source of IL-17 and IL-21, which promote further production of IL-17A, IL-17F and granulocyte-macrophage colony-stimulating factor (GM-CSF) by T H 17 cells 59 . Consistent with these data from mice, γδ T cells are approximately 10-fold enriched (relative to blood) in CNS lesions in patients with early MS, where they make up 20-30% of the lesional T cell population 60 and are able to produce IL-17 to promote autoimmunity 61 . However, some γδ T cells can have immunoregulatory effects by promoting apoptosis in autoreactive αβ T cells in a manner dependent on the interaction between Fas (also known as TNF receptor superfamily member 6) and its ligand FasL (also known as TNF superfamily member 6) 62 . Similarly to findings in the context of MS, IL-17-producing γδ T cells have a pathogenic role in mouse models of psoriasis and have been detected in the skin lesions of patients with psoriasis, although they are rare 63, 64 . The main sources of IL-17 in human skin diseases are thought to be ILCs, neutrophils and mast cells (reviewed elsewhere 65 ). Considering rheumatic autoimmune diseases, evidence for the involvement of γδ T cells in RA and juvenile idiopathic arthritis (JIA) is conflicting. Some results suggest that the high proportion of γδ T cells in JIA synovium contributes to TNF and IFNγ production in the joint 66 , whereas others indicate that the proportion of subtypes of γδ T cells is altered in patients with RA, with Vγ2Vδ2 T cells being protective and Vγ1Vδ1 T cells contributing to pathogenesis 67 . Clearly, more work is needed to determine exactly which γδ T cell subtypes are immune-protective and which contribute to autoimmunity before γδ T cell-targeting therapies can be developed.
MAIT cells
Despite their name, MAIT cells are a major subset of human peripheral blood T cells, and they are usually more frequent than γδ T cells: MAIT cells account for ~5-10% of human peripheral blood T cells [68] [69] [70] , whereas γδ T cells account for ~2-5% 50, 51 . MAIT cells are restricted by the non-polymorphic non-classical MHC class I-related molecule MR1, which presents bacterial vitamin metabolite ligands 68, 69 . Functionally, MAIT cells are mostly cytotoxic CD8 + cells, although a small proportion of MAIT cells are double-negative (CD4   -CD8   -) and produce large amounts of mostly proinflammatory cytokines such as IFNγ and IL-17 24 .
Although the number of circulating MAIT cells is reduced in patients with RA compared with healthy controls, MAIT cell numbers in the synovial fluid from RA patients are considerably higher than in matched peripheral blood samples 70 . Furthermore, both collagen-induced arthritis (CIA) and collagen antibodyinduced arthritis are less severe in MAIT-cell-deficient Mr1-knockout mice than in normal Mr1-replete controls 71 . Of note, in this study, MAIT cells were stimulated by IL-23 or IL-1β in the absence of TCR stimuli; cytokine-stimulated MAIT cell activation provides a general mechanism for these cells to contribute to sterile inflammation in the absence of infection.
Interestingly, and conversely to NKT cells, glucocorticoids suppress MAIT cell proliferation, which could complicate the analysis of MAIT cells in gluco corticoidtreated patients 72 . Furthermore, MAIT cells and other innate lymphocytes, as well as approximately 25% of adult human T cells, show downregulation of CD161 in response to activation 72 , although this is particularly relevant to MAIT cells, as CD161 is regularly used to identify them. Studies that find a reduced frequency of MAIT cells should take this finding into consideration, as it might reflect a reduction in CD161 expression rather than a true reduction in the number of MAIT cells.
ILB cells
Similarly to T cells, B cells can possess regulatory and innatelike properties. Several ILB cell subsets exist, with the number of subsets depending on how 'innate' is defined 73, 74 . Here we discuss B1 cells, marginal zone B cells, B10 cells and innate response activator (IRA) B cells. In these cell subsets, the B cell receptor undergoes minimal or no V(D)J rearrangement; indeed, some B cell receptors are encoded in germline DNA, thus they are categorized as innate-like. B1 cells are able to produce natural IgM, which are polyclonal antibodies that are found in healthy, steady-state conditions and have roles in maintaining homeostasis and clearing apoptotic cells 75 . Marginal zone B cells of the spleen can rapidly produce natural IgM after stimulation with Toll-like receptor (TLR) ligands 76 , thereby acting as a first-line defence against bacterial infection. B10 cells are so named because they produce IL-10, an antiinflammatory cytokine 77 . IRA B cells respond to bacterial pathogen-associated molecular patterns by producing GM-CSF, and depletion of IRA B cells leads to reduced bacterial clearance and septic shock in mice 74 . Given the expanding technology involved in immunophenotyping (reviewed elsewhere 78 ) , the number of different types of ILB cell is expected to rise, and it is likely that in the future we will learn more about their diverse roles in immune regulation and in front-line responses to infections.
As with other innate lymphocytes, ILB cells have been implicated in autoimmune diseases. Currently, such data only exist for B1 cells and B10 cells. SLE is characterized by autoantibody production, and therefore how B cells lose tolerance is of great research interest. Many studies have reported that pathogenic B1 cells in mice contribute to autoimmunity in models of lupus and lupus nephritis (reviewed elsewhere 79, 80 ). In patients with SLE, although not directly implicated in this disease, B1 cells have been found in expanded numbers in blood, and they have been shown to upregulate their expression of CD86 and thereby provide co-stimulation to T cells 81 . By contrast, B10 cells have been found in reduced numbers in the peripheral blood of patients with type 1 diabetes mellitus 82 and psoriasis 83 . B10 cells are thought to have a role similar to T reg cells in inhibiting autoimmunity 77 . In addition, ex vivo stimulation of B10 cells from patients with SLE revealed that they produce more IL-10 than those from healthy controls 84 . Therefore, B1 cells and B10 cells seem to have different roles in the autoimmune diseases in which they have been studied so far. Future work is needed to further elucidate their contributions and those of other ILB cell subsets. As mentioned above, in relation to other innate lymphocyte subsets, the effect of treatments such as glucocorticoids is an important consideration.
Innate lymphocytes and biologic therapies
Biologic drugs target the immune system by either 'mopping up' proinflammatory cytokines (such as TNF, IL-6 and IL-17) or by abrogating the adaptive immune response (via B cell reduction therapy or T cell costimulation blockade). The rapid increase in the number of biologic therapies for autoimmune diseases, coupled with the discovery of novel subsets of innate lymphocytes, has led investigators to question how biologic drugs are affecting these cells on a mechanistic level. This question remains largely unanswered. However, some studies have investigated potential correlations between the numbers of NK cells in peripheral blood and patient responses to treatment with various conventional DMARDs and biologic drugs. For instance, one group found that changes in the proportion of CD56 hi CD16 − NK cells predicted response to tocilizumab therapy after 3 months in patients with RA 85 . The human CD56 hi NK cell subset, best known for secreting proinflammatory factors rather than for cytotoxic activity, is associated with responses to biologic therapies in MS 85 . These data suggest that the proportion and phenotype of subsets of innate lymphocytes might be able to predict patient responses to different biologic drugs.
Prospects for therapeutic targeting
Several proinflammatory mediators that are produced by innate lymphocytes contribute to the development of autoimmune disease (against a background of failed immunoregulation), for example GM-CSF 86 and TNF (TABLE 1) . In particular TNF is a prototypical example and was one of the first proinflammatory cytokines linked with RA (by far the most common autoimmune disease) back in early 1990s 86 . The success of TNF-targeting biologic therapies has dramatically altered treatment algorithms in rheumatology (reviewed elsewhere 86 ). More recently, the IL-17, IL-23, TGFβ and IL-1β axis has been implicated in autoimmune inflammation 87 . IL-33 or its receptor, IL-1 receptor-like 1 (also known as protein ST2) might also represent therapeutic targets in some autoimmune rheumatic diseases. For example, serum IL-33 and soluble ST2 levels are elevated in patients with primary Sjögren syndrome compared with patients with SLE as well as healthy controls 88 . In vitro, IL-33 alone did not increase proinflammatory cytokine secretion, but IL-33 acted synergistically with IL-12 and IL-23 to promote IFNγ production 88 . However, disappointing results from clinical trials of agents that inhibit some of the discussed cytokines have suggested redundancy in these cytokine pathways 89 . As sources of and targets for some of these cytokines, innate lymphocytes represent alternative therapeutic targets in autoimmune diseases (TABLE 2) . In particular, there is much interest in potent and specific iNKT ligands such as α-GalCer in the application of cancer immunotherapy and immunomodulation of autoimmune disease (reviewed elsewhere 90 ). For instance, in a mouse model, administration of α-GalCer reduced the occurrence of experimental autoimmune myasthenia gravis in susceptible animals from 91% to 30% 91, 92 . Similarly, and remarkably, a single dose of α-GalCer or the T H 1-polarizing analogue α-C-GalCer during the induction phase of CIA had therapeutic efficacy in DBA/1 mice 93 . Neutralization of IFNγ at an early stage of disease resulted in partial improvement of arthritis, whereas later blockade resulted in more rapid improvement, implicating IFNγ in the therapeutic mechanism. Also, upon systemic anti-CD3 stimulation, T cells from α-GalCer-treated mice produced substantially higher levels of IL-10 than those from phosphate buffered saline-treated controls; by contrast, T cells from α-C-GalCer-treated mice produced lower levels of IFNγ, TNF and RANK ligand (RANKL, also known as TNF ligand superfamily member 11), suggesting different therapeutic mechanisms. Consistent with these results, α-GalCer also significantly reduced the severity of disease in two other models of CIA 94, 95 . Therefore, in certain mouse models of autoimmunity, in vivo administration of iNKT cell ligands can ameliorate disease, supporting a role of iNKT cells in immunoregulation of such diseases. However, this therapeutic role of iNKT cells is of course distinct from their involvement in the pathogenesis of the underlying disease.
Although they are heterogeneous, innate lymphocytes are far less diverse than adaptive B cells and T cells, which have been successfully, albeit broadly, targeted, for example, using rituximab (reviewed elsewhere 96 ) in autoimmune diseases such as SLE. Notably, NK cells, iNKT cells and γδ T cells have been safely targeted in patients with cancer, and some trials have provided evidence of objective responses to approaches targeting each of these cell subsets 8, 15, 26, 50 . Thus, we propose that innate lymphocyte subsets represent attractive targets in the context of autoimmune disease (TABLE 2) that could offer a therapeutic benefit with a favourable balance of efficacy and safety, which always presents a challenge in patients with autoimmune disease Another challenge relates to our ability to control dosing; particularly in autoimmunity, the ability to 'switch off ' a therapy urgently in patients who develop acute infections or disease exacerbations would provide added confidence when targeting specific cell subsets. For example, small molecules typically have a short half-life in vivo, but many antibody-based therapies can stay in circulation for weeks 86 . Specific 'anti-antibodies' might be used to deplete therapeutic antibodies when unwanted side effects appear, just as spontaneous anti-antibodies limit the effectiveness of therapeutic antibodies 97, 98 . As well as offering potential novel therapies, increasing interest in gene editing (including editing somatic tissues using CRISPR-Cas9 technology and other approaches 99 ) and cell therapies intensifies the need for 'kill switches' for both approaches.
Conclusions
In summary, the immune system contributes to protective inflammation, but inflammation can become chronic in response to prolonged stimulation with exogenous antigens or autoantigens and can contribute to disease. Similarly to TNF and other effector molecules, proinflammatory innate lymphocytes probably contribute to the pathogenesis of autoimmune disease and might thus be appropriate therapeutic targets. Conversely, innate lymphocytes that primarily have a regulatory role in the context of autoimmunity could offer targets for agonism in autoimmune diseases. We envisage that elucidating the different positive and negative roles of innate lymphocytes in autoimmune diseases will offer rheumatologists novel therapeutic approaches in the near future.
